Q Ventures

What Q Ventures does

Q Ventures (钱塘创投), also rendered in English as Qiantang Ventures, is a privately-held venture capital firm headquartered in the Qiantang New Area of Hangzhou, Zhejiang Province, China. The firm focuses exclusively on early-stage and Pre-IPO investments in two verticals: bio-pharmaceuticals and next-generation electronic information technology, with an emphasis on semiconductors. Q Ventures currently operates a dual-currency fund platform comprising two RMB-denominated funds and one USD-denominated fund, reflecting a stated strategy of connecting overseas advanced technology with China's domestic market opportunity. Investment screening is oriented toward founders described as "both scientists and entrepreneurs" and toward companies exhibiting "unique innovation capability in emerging industries."

The firm does not develop proprietary technology products; its outputs are capital allocation, portfolio support, and strategic guidance. Its portfolio spans neural cell therapy (HuoDe Bio/霍德生物), drug development services (Heze Pharm/和泽医药), genomic target enrichment (Paragon Genomics), AI-powered protein structure design (Zelixir/智峪生科), 3D bioprinting (Regenovo/捷诺飞), gout therapeutics (Arthrosi Therapeutics), GPU chip development (砺算科技/TrueGPU), and holographic imaging (Xianghang Technology/像航科技). Q Ventures monetizes via traditional VC fund economics — management fees on committed capital and carried interest on exits — sourced from a limited partner base that includes institutional investors and family offices; specific fund sizes, AUM, and LP composition are not publicly disclosed.

The firm operates with a small core team of 1-10 employees, including seven publicly named investment professionals, and reaches the market primarily through direct LP relationships, industry events, and a basic corporate website (qiantangventures.com). Public positioning emphasizes sector specialization and cross-border deal origination rather than brand-led fund marketing.

Name

Q Ventures

Legal name

钱塘创投

Website

https://qiantangventures.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Venture Capital

NAICS

Miscellaneous Financial Investment Activities (523999), All Other Financial Investment Activities (52399)

SIC

Investment Advice (6282)

akta.pro primary industry

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

akta.pro secondary industry

Early-Stage Venture Capital (Series A/B) (FSANAAAB)

Keywords

• Venture capital investing
• Early-stage equity investment
• Biotechnology venture funding
• Semiconductor venture investing
• Pre-IPO investment

Headquarters

HQ city

Hangzhou

HQ country

China

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations

Distribution channels1 record

Marketing channels2 records

Core offering

Q Ventures (钱塘创投) is a venture capital firm that manages 2 RMB-denominated funds and 1 USD-denominated fund, deploying capital into early-stage and Pre-IPO projects. Its investments are concentrated in two sectors: bio-pharmaceuticals and next-generation electronic information technology (semiconductors). The firm also provides strategic guidance to portfolio companies and acts as a bridge connecting overseas advanced technology with China's domestic market.

Product overview

Q Ventures (钱塘创投) is a venture capital firm that manages 2 RMB funds and 1 USD fund, focusing investment on overseas early-stage and Pre-IPO projects in bio-pharmaceuticals and next-generation electronic information technology (semiconductors). As an investment firm, Q Ventures does not offer its own technology products or services; rather, it provides capital and strategic support to portfolio companies developing various technologies including neural cell therapy, drug development services, genomic target enrichment, AI-powered protein structure design, 3D bioprinting, GPU chips, computational storage, holographic imaging technology, and semiconductor interconnect solutions.

Differentiator

Problem solved

Functional benefit

Products and services

• RMB Venture Capital Funds (2 funds) RMB-denominated venture capital funds deployed into early-stage and Pre-IPO projects in bio-pharmaceuticals and next-generation electronic information technology (semiconductors). Available to onshore Chinese institutional investors and family offices as limited partners.
• USD Venture Capital Fund (1 fund) USD-denominated venture capital fund deployed into early-stage and Pre-IPO projects in bio-pharmaceuticals and next-generation electronic information technology (semiconductors), with a focus on overseas technology companies seeking to access the China market. Available to institutional investors and family offices as limited partners.
• Equity Investment in Portfolio Companies Equity capital investments and strategic guidance provided to early-stage and Pre-IPO portfolio companies in biotechnology and semiconductor sectors, with a particular focus on founders who are both scientists and entrepreneurs, and on bridging overseas advanced technology with China's market.

Quantifiable outcome

• Successfully invested in multiple unicorn and potential unicorn companies including ScaleFlux, HuoDe Bio, and Xianghang Technology

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Direct peers

• Linear Venture (线性资本): China-based early-stage venture capital firm focused on enterprise services, deeptech, and frontier technology, with a comparable team size and early-stage, sector-focused investment approach.
• ZhenFund (真格基金): One of China's most active early-stage VC firms, focused on technology and biotech seed-to-Series A deals; highly comparable fund size and stage orientation.
• Northern Light Venture Capital (北极光创投): China-based early-stage VC investing in tech, biotech, and clean technology; directly comparable vertical breadth and early-stage thesis.
• Matrix Partners China (经纬创投): Established early-stage Chinese VC with biotech and semiconductor exposure, comparable in stage focus and sector breadth though larger in scale.

Broad incumbents

• Legend Capital (君联资本): Large Chinese VC/PE firm with significant biotech and TMT exposure; a broader incumbent providing scale and exit infrastructure that Q Ventures' portfolio companies can plug into.
• Hillhouse Capital (高瓴资本): Mega Chinese investment platform with deep biotech and semiconductor allocations; relevant as a benchmark for AUM scale and exit pathways.
• IDG Capital (IDG资本): Long-standing Chinese VC firm with cross-stage biotech, semiconductor, and enterprise tech investing, broadly comparable in mandate though much larger.
• Shenzhen Capital Group (深创投): State-backed Chinese VC with broad sector exposure including biotech and semiconductors; comparable early-stage orientation but with materially larger fund base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Q Ventures